Vyvanse Bed denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvanse bed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Vyvanse for BED on Medical-Necessity Grounds

Blue Cross Blue Shield medical-necessity denials for Vyvanse in binge eating disorder almost always come down to insufficient documentation reaching the plan reviewer. The reviewer may not have seen evidence that the diagnosis meets the plan's required severity level, that prior treatments were tried and failed, or that a qualified clinician has determined this medication is the appropriate next step. The plan may also apply criteria tied to its own coverage policy, which can include behavioral or dietary intervention requirements before medication is authorized.

## Why This Denial Is Appealable

Medical-necessity determinations are among the most successfully appealed denial categories because they depend on clinical evidence — and clinical evidence is within your prescriber's power to supply. A well-constructed appeal that maps your chart documentation against every criterion in the plan's coverage policy gives an internal reviewer, or an independent external reviewer, a clear basis to approve.

## Federal Appeal Framework

• Internal appeal — you typically have 180 days from denial receipt; check your denial letter for the exact deadline.
• External review (ACA §2719) — after a final internal denial on a fully-insured BCBS plan, you may request independent external review; the window is approximately four months. An external reviewer applies objective medical standards, not the plan's proprietary criteria alone.
• ERISA §503 — self-funded plans must conduct a full-and-fair review and provide a specific written rationale for any continued denial.
• Expedited option — available if the standard timeline would seriously jeopardize your health or ability to function.

## Documentation to Gather

1. Formal BED diagnosis — DSM-5-compliant clinical documentation confirming diagnosis and severity (moderate or severe), dated and signed. 2. Prior-treatment history — a chronological list of all prior behavioral, dietary, and pharmacologic treatments with start/stop dates and documented outcomes or reasons for discontinuation. 3. Clinical severity documentation — chart notes showing frequency, impairment, and impact on daily functioning. 4. Prescriber medical-necessity letter — a detailed letter explaining the clinical rationale for Vyvanse specifically, why alternatives are insufficient, and how the patient meets criteria per the FDA-approved label and the applicable professional society guidelines (e.g., APA or eating-disorder-focused society guidance). 5. FDA prescribing label — include the labeled BED indication to confirm this is an approved, non-experimental use.

## Criteria-Mapping Structure

Download BCBS's current coverage policy for Vyvanse or for BED pharmacotherapy. List every stated criterion. For each, write the criterion verbatim, then the supporting chart fact beneath it. Common criteria to address: confirmed diagnosis and severity, documented failure of or contraindication to first-line behavioral approaches, prescriber specialty or referral basis, and absence of conditions the plan uses to exclude coverage. A clean one-to-one mapping is far more persuasive than a narrative letter that forces the reviewer to hunt for answers.